Neal J Meropol, MD

Recent Publications
As Of May 25, 2007

In Press

Tolcher AW, Mita M, Meropol NJ, von Mehren M, Patnaik A, Padavic K, Hill M, Mays T, McCoy T, Fox NL, Halpern W, Corey A, and Cohen RB. Mapatumumab, a fully human monoclonal antibody with agonist activity to TRAIL-R1: a phase I, pharmacokinetic and biologic correlative study. J Clin Oncol, in press.

Buzaglo JS, Millard JL, Ridgway CG, Ross EA, Antaramian SP, Miller SM, Meropol NJ. An internet method to asses cancer patient information needs and enhance doctor-patient communication: a pilot study. J Cancer Educ, in press.

Coups EJ, Manne SL, Meropol NJ, Weinberg DS. Multiple behavioral risk factors for colorectal cancer and colorectal cancer screening status. Cancer Epidemiology, Biomarkers & Prevention, in press.

Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, and Benson III, AB. Bevacizumab in combination with oxaliplatin, fluorouracil and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group study E3200. J Clin Oncol, in press.

Berencsi K, Meropol NJ, Hoffman JP, Sigurdson E, Giles L, Rani P, Somasundaram R, Zhang T, Kalabis J, Caputo L, Furth E, Swoboda R, Marincola F, Herlyn D. Colon carcinoma cells induce CXCL11-dependent migration of CXCR3-expressing cytotoxic T lymphocytes in organotypic culture. Cancer Immunol Immunother, in press.

Buzaglo JS, Millard JL, Ridgway CG, Ross EA, Antaramian SP, Miller SM, Meropol NJ. An internet method to assess cancer patient information needs and enhance doctor-patient communication: a pilot study. J Cancer Educ, in press.

Meropol NJ, Buzaglo JS, Millard J, Damjanov N, Miller SM, Ridgway C, Ross EA, Sprandio JD, Watts P. Barriers to clinical trial participation as perceived by oncologists and patients. J NCCN, in press.

Konski AA, Cheng JD, Goldberg M, Li T, Maurer A, Yu JQ, Haluszka O, Scott W, Meropol NJ, Cohen SJ, Freedman G, Weiner LM. Correlation of molecular response as measured by 18-FDG PET with outcome after chemo-radiation in patients with esophageal carcinoma. Int J Rad Oncol Biol Physics, in press.

Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, Wong TW, Huang X, Takimoto CH, Godwin AK, Tan BR, Krishnamurthi SS, Burris III HA, Poplin EA, Hidalgo M, Baselga J, Clark EA, and Mauro DJ. Expression of epiregulin and amphiregulin and K-RAS mutation status are associated with disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol, in press.

Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Hecht JR, Patnaik A, Berlin J, Venook A, Malik I, Tchekmedyian S, Navale L, Amado RG, Meropol NJ. Cancer, in press.

2007

Coups EJ, Manne SL, Meropol NJ, Weinberg DS. Multiple behavioral risk factors for colorectal cancer and colorectal cancer screening status. Cancer Epidemiology, Biomarkers & Prevention 16: 510-516, 2007.

Freedman GM, Meropol NJ, Sigurdson ER, Hoffman J, Callahan E, Price R, Cheng J, Cohen S, Lewis N, Watkins-Bruner D, Rogatko A, Konski A. Phase I trial of preoperative hypofractionated intensity-modulated radiotherapy with incorporated boost and oral capecitabine in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 67:1389-93, 2007.

Goldberg RM, Rothenberg ML, Van Cutsem E, Benson III AB, Blanke CD, Diasio RB, Grothey A, Lenz HJ , Meropol NJ, Ramanathan RK, Becerra CHR, Wickham R, Armstrong D, Viele C. The continuum of care: a paradigm for the management of metastatic colorectal cancer. The Oncologist 12:38-50, 2007.

Meropol NJ, Schulman KA. The cost of cancer care: issues and implications. J Clin Oncol, 25:180 186, 2007.

Meropol NJ, Schulman KA. Perspectives on the cost of cancer care. J Clin Oncol 25:169-170, 2007.

Meropol NJ, Schulman KA, Guest editors. Reviews: Perspectives on the cost of cancer care. J Clin Oncol 25 (2), 2007.

2006

Henry LR, Goldberg M, Scott W, Konski A, Meropol NJ, Freedman G, Weiner LM, Watts P, Beard M, McLaughlin S, Cheng JD. Induction cisplatin and paclitaxel, followed by combination chemoradiotherapy with 5-FU, cisplatin, and paclitaxel before resection in localized esophageal cancer: A phase II report. Annals Surgical Oncology 13(2):1-7, 2006

Meropol NJ, Gold PJ, Diasio RB, Andria M. Dhami M, Godfrey T, Kovatich AJ, Lund KA, Mitchell E, Schwarting R. Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer. J Clin Oncol, 24:4069-4077, 2006.

Movsas B, Diratzouian H, Hanlon A, Cooper H, Freedman G, Konski A, Sigurdson E, Hoffman J, Meropol NJ, Weiner L, Coia L, Lanciano R, Stein J, Kister D, Eisenberg B. Phase II trial of preoperative chemoradiation with a hyperfractionated radiation boost in locally advanced rectal cancer. Am J Clin Oncol 29:435-441, 2006.

Cohen SJ, Alpaugh RK, Gross S, O'Hara SM, Smirnov DA, Terstappen LWMM, Allard WJ, Bilbee M, Cheng JD, Hoffman JP, Lewis NL, Pellegrino A, Rogatko A, Sigurdson E, Wang H, Watson JC, Weiner LM, Meropol NJ. Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer. Clinical Colorectal Cancer 6:125-132, 2006.

Giantonio BJ, Levy DE, O’Dwyer PJ, Meropol NJ, Catalano PJ, Benson III A.B. A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the eastern cooperative oncology group study E2200. Annals Oncol 17:1399-1403, 2006.

Agrawal M, Grady C, Fairclough DL, Meropol NJ, Maynard K, Emanuel EJ. Patients' decision-making process regarding participation in phase 1 oncology research. J Clin Oncol 24:4479-4484, 2006.

Meropol NJ. A turning point for colorectal cancer clinical trials. J Clin Oncol 24:3322-3324, 2006.

Sundermeyer ML, Lessin SR, Meropol NJ. Targeted therapies in colorectal cancer: complications and management. Current Colorectal Cancer Reports 2:125-133, 2006.

Meropol NJ, Buzaglo JS, Miller SM, Sheth HR, Stearman BJ, Stanton L. Genetic and family-related issues within a complex disease model: colorectal cancer. In S.M. Miller, S. McDaniel, J. Rolland, & S. Feetham (Eds.), Individuals, families and the new era of genetics. New York: W.W. Norton & Company, Inc., pp. 320-342, 2006.

Cohen SJ, Meropol NJ. Targeting EGFR in Colorectal Cancer. Oncology (Suppl), September 2006, pp 1-15.

Raghavan D, Brecher ML, Johnson DH, Meropol NJ, Moots P, Rose P, eds. Textbook of Uncommon Cancer, 3rd ed. John Wiley and Sons, Sussex, England, 2006.

Ajani J, Bekaii-Saab T, D'Amico TA, Fuchs C, Gibson MK, Goldberg M, Hayman JA, Ilson DH, Javle M, Kelley S, Kurtz RC, Locker GY, Meropol NJ, Minsky BD, Orringer MB, Osarogiagbon RU, Posey JA, Roth J, Sasson AR, Swisher SG, Wood DE, Yen Y. Gastric Cancer Clinical Practice Guidelines. J Natl Compr Canc Netw 4:350-66, 2006.

2005

Weinfurt KP, DePuy V, Castel LD, Sulmasy DP, Schulman KA, Meropol NJ. Understanding of an aggregate probability statement by patients who are offered participation in phase I clinical trials. Cancer 103: 140-147, 2005.

Carlini LE, Meropol NJ, Bever J, Andria ML, Hill T, Gold P, Rogatko A, Wang H, Blanchard RL. Genetic variation in human UGTs 1A7 and 1A9 predict for efficacy and toxicity in patients receiving combination capecitabine/irinotecan therapy for the treatment of metastatic colorectal cancer. Clin Cancer Res 11:1226-36, 2005.

Mulcahy MF, Loehrer PJ, Meropol NJ, Rademaker AW, Benson AB. A phase I study of docetaxel, cisplatin, 5-fluorouracil and leucovorin. Oncology 68: 479-484, 2005.

Smirnov DA, Zweitzig DR, Bradley WF, Miller MC, Doyle GV, Pienta KJ, Meropol NJ, Weiner LM, Cohen SJ, Moreno JG, Connelly MC, Terstappen LWMM, O'Hara SM. Global gene expression profiling of circulating tumor cells. Cancer Res 65:4993-97, 2005.

Sundermeyer ML, Meropol NJ, Rogatko A, Wang H, Cohen SJ. Changing patterns of bone and brain metastases in patients with colorectal cancer. Clin Colorectal Cancer, 5:108-113, 2005.

Konski A, Hoffman J, Sigurdson E, Haluszka O, Engstrom P, Cheng JD, Cohen SJ, Watson JC, Eisenberg D, McGarrity E, Freedman G, Meropol NJ. Can molecular imaging predict response to preoperative chemoradiation in patients with rectal cancer? A Fox Chase Cancer Center prospective experience. Semin Oncol 32 (6 Suppl 9): 63-67, 2005.

Meropol NJ. EGFR inhibitors in colorectal cancer: it's time to get back on target. J Clin Oncol, 23:1791 1793, 2005.

Meropol NJ. Colorectal cancer: looking forward. Semin Oncol. 32: 1-2, 2005.

Meropol NJ, Desmond-Hellmann S, Tunis S, Schulman KA. Can society afford state of the art cancer care? ASCO Education Book, 2005.

Cohen SJ, Cohen RB, Meropol NJ. Targeting signal transduction pathways in colorectal cancer - more than skin deep. J Clin Oncol, 23:5374-5385, 2005.

Denlinger CS, Meropol NJ. Review of: The horizon of antiangiogenic therapy for colorectal cancer, by Olszewski, Grossbard, Kozuch. Oncology 19:329-333, 2005.

Meropol NJ, Guest Editor. Colorectal Cancer: From Prevention to Treatment. Seminars in Oncology 32 (1), 2005.

2004

Cohen, S.J., Gallo, J., Lewis, N.L., Alpaugh, R.K., Gentner, L., Rogatko, A., Yeslow, G., Schol, J., Verhaeghe T., Zannikos, P., Palmer, P.A., Weiner, L.M., Meropol, N.J. Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer. Cancer Chemother. Pharmacol. 53:513-518, 2004.

Damjanov, N., Meropol, N.J. Epidermal growth factor receptor inhibitors for the treatment of colorectal cancer: a promise fulfilled? Oncology 18:479-488, 2004.

Gaskin, D.J., Weinfurt, K.P., Castel, L.D., DePuy, V., Li, Y., Balshem, A., Benson, A., Burnett, C.B., Corbett, S., Marshall, J., Slater, E., Sulmasy, D.P., Van Echo, D., Meropol, N.J., Schulman, K.A. An exploration of relative health stock in advanced cancer patients. Med. Decis. Making 24:614-624, 2004.

Ibanez de Caceres, I., Frolova, N., Varkonyi, R.J., Dulaimi, E., Meropol, N.J., Broccoli, D., Cairns, P. Telomerase is frequently activated in tumors with microsatellite instability. Cancer Biol. Ther. 3:289-292, 2004.

Meropol, N.J., Castel, L., Schulman, K.A., Weinfurt, K.P. Physician-patient communication in phase I cancer trials. Response to correspondence. J. Clin. Oncol. 22:572-573, 2004.

Saltz, L.B., Meropol, N.J., Loehrer, P.J. Sr., Needle, M.N., Kopit, J., Mayer, R.J. Phase II trial of cetuximab (C225, Erbitux™) in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 22:1201-1208, 2004.

Sasson, A.R., Wetherington, R.W., Hoffman, J.P., Ross, E.A., Cooper, H., Meropol, N.J., Freedman, G., Pingpank, J.F., Eisenberg, B.L. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas. Int. J. Gastrointest. Cancer 34:121-127, 2004.

Shields, A.F., Zalupski, M.M., Marshall, J.L., Meropol, N.J. Treatment of advanced colorectal cancer with oxaliplatin and capecitabine: A phase II trial. Cancer 100:531-537, 2004.

Subhi, A.L., Tang, B., Balsara, B.R., Altomare, D.A., Testa, J.R., Cooper, H.S., Hoffman, J.P., Meropol, N.J., Kruger, W.D. Loss of methylthioadenosine phosphorylase and elevated ornithine decarboxylase is common in pancreatic cancer. Clin. Cancer Res. 10:7290-7296, 2004.

Meropol NJ, Castel L, Schulman KA, Weinfurt KP. Physician-patient communication in phase I cancer trials. Response to correspondence. J Clin Oncol 22: 572-573, 2004.

Damjanov N, Meropol NJ. Epidermal growth factor receptor inhibitors for the treatment of colorectal cancer: a promise fulfilled? Oncology, 18:479-488, 2004.

2003

Cohen, S.J., Ho, L., Ranganathan, S., Abbruzzese, J.L., Alpaugh, K., Beard, M., Lewis, N.L., McLaughlin, S., Rogatko, A., Ruixo, J.J.P., Thistle, A.M., Verhaeghe, T., Wang, H., Weiner, L.M., Wright, J.J., Hudes, G.R., Meropol, N.J. Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J. Clin. Oncol. 21:1301-1306, 2003.

Cohen, S.J., Meropol, N.J. Commentary: understanding and managing chemotherapy-induced diarrhea. J Supportive Oncol. 1:38-41, 2003.

Cortellino, S., Turner, D., Masciullo, V., Schepis, F., Albino, D., Daniel, R., Skalka, A.M., Meropol, N.J., Alberti, C., Larue, L.,

Bellacosa, A. The base excision repair enzyme MED1 mediates DNA damage response to anti-tumor drugs and is associated with mismatch repair system integrity. Proc. Natl. Acad. Sci. USA 100:15071-15076, 2003.

Kabbinavar, F., Hurwitz, H.I., Fehrenbacher, L., Meropol, N.J., Novotny, W.F., Lieberman, G., Griffing Bergsland, E. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol. 21:60-65, 2003.

Lewis, N.L., Meropol, N.J. Development of new agents for the treatment of advanced colorectal cancer. Clin Colorectal Cancer 3:154-64, 2003.

Mandelblatt, J.S., Edge, S.B., Meropol, N.J., Senie, R., Tsangaris, T., Grey, L., Peterson, B.M. Jr., Hwang, Y.T., Kerner, J., Weeks, J. Predictors of long-term outcomes in older breast cancer survivors: perceptions versus patterns of care. J. Clin. Oncol. 21:855-63, 2003.

Manne, S., Markowitz, A., Winawer, S., Guillem, J., Meropol, N.J., Haller, D., Rakowski, W., Babb, J., Jandorf, L., Duncan, T. Understanding intention to undergo colonoscopy among intermediate risk siblings of colorectal cancer patients: a test of a mediational model. Prev. Med. 36:71-84, 2003.

Meropol, N.J., Weinfurt, K.P., Burnett, C.B., Balshem, A., Benson, A.B., III, Castel, L., Corbett, S., Diefenbach, M., Gaskin, D., Li, Y., Manne, S., Marshall, J., Slater, E., Sulmasy, D.P., Rowland, J.H., Van Echo, D., Washington, S., Schulman, K.A. Perceptions of patients and physicians regarding phase I cancer clinical trials: implications for physicianpatient communication. J. Clin. Oncol. 21:2589-2596, 2003.

Meropol, N.J., Somer, R.A., Gutheil, J., Pelley, R.J., Modiano, M.R., Rowinsky, E.K., Rothenberg, M.L., Redding, S.W., Serdar, C.M., Yao, B., Heard, R., Rosen, L.S. Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. J. Clin. Oncol. 21:1452-1458, 2003.

Meropol, N.J., Weinfurt, K.P., Schulman, K.A. Phase I trials: physician and patient perceptions. Response to correspondence. J. Clin. Oncol. 21:4659-4660, 2003.

Schuchter, L., Meropol, N.J., Winer, E.P., Hensley, M.L., Somerfield, M.R. Amifostine and chemoradiation therapy: ASCO responds. Lancet Oncol. 4:593, 2003.

Weinfurt, K.P., Castel, L.D., Li, Y., Sulmasy, D.P., Balshem, A., Benson, III A.B., Burnett, C.B., Gaskin, D.J., Marshall, J.L., Slater, E., Schulman, K.A., Meropol, N.J. The relationship between patient characteristics and expectations of benefit from phase I clinical trials. Cancer 98:166-175, 2003.

Weinfurt, K.P., Sulmasy, D.P., Schulman, K.A., Meropol, N.J. Patient expectations of benefit from phase I clinical trials: linguistic considerations in diagnosing a therapeutic misconception. Theoretical Med. Bioethics 24:329-344, 2003.

Lewis NL, Meropol NJ. Development of new agents for the treatment of advanced colorectal cancer. Clin Colorectal Cancer, 3:154-164, 2003.

Cohen SJ, Meropol NJ. Commentary: understanding and managing chemotherapy-induced diarrhea. J Supportive Oncol 1:38-41, 2003.

Schuchter L, Meropol NJ, Winer EP, Hensley ML, Somerfield MR. Amifostine and chemoradiation therapy: ASCO responds. Lancet Oncol, 4:593, October 2003.

Meropol NJ, Weinfurt KP, Schulman KA. Phase I trials: physician and patient perceptions. Response to correspondence. J Clin Oncol 21: 4659-4660, 2003.

2002

Arnoletti, J.P., Hoffman, J.P., Ross, E.A., Kagan, S.A., Meropol, N.J., Freedman, G., Eisenberg, B. Preoperative chemoradiation in the management of adenocarcinoma of the body of the pancreas. Am. Surg. 68:330-335, 2002.

Cohen, S.J., Leichman, C.G., Yeslow, G., Beard, M., Proefrock, A., Roedig, B., Damle, B., Letrent, S.P., DeCillis, A.P., Meropol, N.J. Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer. Clin. Cancer Res. 8:2116-2122, 2002.

Cohen, S.J., Meropol, N.J. Drug development in pancreatic cancer: finally, biology begets therapy. Int. J. Gastrointest. Cancer 32(2-3):91-106, 2002.

Edge, S.B., Gold, K., Berg, C., Meropol, N.J., Tasangaris, T., Gray, L., Peterson, B., Hwang, Y-T., Mandelblatt, J.S. Patient and provider characteristics affecting use of axillary dissection in older women with stage I/II breast cancer. Cancer 94:2534-2544, 2002.

Fleming G.F., Meropol, N.J., Rosner, G.L., Hollis, D.R., Carson, W.E. 3rd, Caligiuri, M., Mortimer, J., Tkaczuk, K., Parihar, R., Schilsky, R.L., Ratain, M.J. A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of Cancer and Leukemia Group B 9661. Clin. Cancer Res. 8: 3718-27, 2002.

Lewis, N.L., Scher, R., Gallo, J.M., Engstrom, P.F., Szarka, C.E., Litwin, S., Adams, A.L., Kilpatrick, D., Brady, D., Weiner, L.M., Meropol, N.J. Phase I and pharmacokinetic study of irinotecan in combination with raltitrexed. Cancer Chemother. Pharmacol. 50:257-265, 2002.

Liang, W., Burnett, C.B., Rowland, J.H., Meropol, N.J., Eggert, L., Hwang, Y., Silliman, R.A., Weeks, J.C., Mandelblatt, J.S. Communication between physicians and older women with localized breast cancer: implications for treatment and patient satisfaction. J. Clin. Oncol. 20:1008-1016, 2002.

Mandelblatt, J.S., Edge, S.B., Meropol, N.J., Senie, R., Tsangaris, T., Grey, L., Peterson, B., Hwang, Y.T., Weeks, J.C. Sequelae of axillary lymph node dissection in older women with stage 1 and 2 breast carcinoma. Cancer 95:2445-54, 2002.

Manne, S., Markowitz, A., Winawer, S., Meropol, N.J., Haller, D., Rakowski, W., Babb, J., Jandorf, L. Correlates of colorectal cancer screening compliance and stage of adoption among siblings of individuals with early onset colorectal cancer. Health Psychol. 21:3-15, 2002.

Meropol, N.J., Lewis, N.L., Frucht, H. Colorectal cancer: a practical overview. Mosby Medical Communications, Philadelphia, 2002.

Pecora, A.L., Rizvi, N., Cohen, G.I., Meropol, N.J., Sterman, D., Marshall, J.L., Goldberg, S., Gross, P., O'Neil, J.D., Groene, W.S., Roberts, M.S., Rabin, H., Bamat, M.K., Lorence, R.M. A Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J. Clin. Oncol. 20(9):2251-2266, 2002.

Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S. Mortality associated with irinotecan plus bolus 5-fluorouracil/leucovorin. Response to correspondence. J. Clin. Oncol. 20:1145-1146, 2002.

Schuchter, L.M., Hensley, M.L., Meropol, N.J., Winer, E.P., for the American Society of Clinical Oncology Chemotherapy and Radiotherapy Protectants Expert Panel. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J. Clin. Oncol. 20:2895-2903, 2002.

Cohen SJ, Meropol NJ. Drug development in pancreatic cancer: finally, biology begets therapy. Int J Gastrointest Cancer 32:91-106, 2002.

Meropol NJ, Lewis NL, Frucht H. Colorectal cancer: a practical overview. Mosby Medical Communications, Philadelphia, 2002.

Schuchter LM, Hensley ML, Meropol NJ, Winer EP, for the American Society of Clinical Oncology Chemotherapy and Radiotherapy Protectants Expert Panel. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 20: 2895-2903, 2002.

Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S. Mortality associated with irinotecan plus bolus 5-fluorouracil/leucovorin. Response to correspondence. J Clin Oncol 20: 1145-1146, 2002.

2001

Balsara, B.R., Pei, J., De Rienzo, A., Simon, D., Tosolini, A., Lu, Y.Y., Shen, F.M., Fan, X., Lin, W.Y., Buetow, K.H., London, W.T., Testa, J.R. Human hepatocellular carcinoma is characterized by a highly consistent pattern of genomic imbalances, including frequent loss of 16q23.1-24.1. Genes Chromosomes Cancer 30:245-253, 2001.

Bellacosa, A. Functional interactions and signaling properties of mammalian DNA mismatch repair proteins. Cell Death Differ. 8:1076-1092, 2001.

Burnett, C.B., Koczwara, B., Pixley, L., Blumenson, L.E., Hwang, Y.T., Meropol, N.J. Nurses' attitudes toward clinical trials at a comprehensive cancer center. Oncol. Nurs. Forum 28(7):1187-1192, 2001.

Clapper, M.L., Chang, W-C., Meropol, N.J. Chemoprevention of colorectal cancer. Curr. Opin. Oncol. 13:307-313, 2001.

Cooper, H.S., Everley, L., Chang, W-C., Pfeiffer, G., Lee, B., Murthy, S., Clapper, M.L. The role of mutant Apc in the development of dysplasia and cancer in the mouse model of dextran sulfate sodium-induced colitis. Gastroenterology 121:1407-1416, 2001.

Drummond, J.T., Bellacosa, A. Human DNA mismatch repair in vitro operates independently of methylation status at CpG sites. Nucl. Acids Res. 29:2234-2243, 2001.

Fava, T., Desnoyers, R., Schulz, S., Park, J., Weinberg, D., Mitchell, E., Waldman, S.A. Ectopic expression of GC-C in CD34+ progenitor cells in peripheral blood. J. Clin. Oncol. 19:3951-3959, 2001.

Fiumicino, S., Ercoli, A., Ferrandina, G., Hess, P., Raspaglio, G., Genuardi, M., Rovella, V., Bellacosa, A., Cicchillitti, L., Mancuso, S., Bignami, M., Scambia, G. Microsatellite instability is an independent indicator of recurrence in sporadic stage I-II endometrial adenocarcinoma. J. Clin. Oncol. 19:1008-1014, 2001.

Lucci-Cordisco, E., Carrara, S., Rovella, V., Del Tin, L., Percesepe, A., Pedroni, M., Caluseriu, O., Bellacosa, A., Anti, M., Neri, G., Ponz de Leon, M., Viel, A., Genuardi, M. Mutations of the minor mismatch repair gene MSH6 in typical and atypical hereditary non-polyposis colorectal cancer. Familial Cancer 1(2):93-9, 2001.

Mandelblatt, J.S., Berg, C.D., Meropol, N.J., Edge, S.B., Gold, K., Hwang, Y-T., Hadley, J. Measuring and predicting surgeons' practice styles for breast cancer treatment in older women. Medical Care 39:228-242, 2001.

Mandelblatt, J.S., Bierman, A.S., Gold, K., Zhang, Y., Ng, J.H., Maserejan, N., Hwang, Y-T., Meropol, N.J., Hadley, J., Silliman, R.A. Constructs of burden of illness in older breast cancer patients: a comparison of measurement methods. Health Services Res. Dec;36(6 Pt 1):1085-107, 2001.

Meropol, N.J., Niedzwiecki, D., Hollis, D., Schilsky, R.L., Mayer, R.J. Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal cancer. Cancer 91:1256-1263, 2001.

Myers, R.E., Turner, B., Weinberg, D., Hauck, W.W., Hyslop, T., Brigham, T., Rothermel, T., Grana, J., Schlackman, N. Complete diagnostic evaluation in colorectal cancer screening: research design and baseline findings. Prev. Med. 33:249-260, 2001.

Newschaffer, C.J., Topham, A., Weiner, S., Herzberg, T., Weinberg, D.S. The risk of colorectal cancer after breast cancer. Lancet 357:837-840, 2001.

Pingpank, J.F., Hoffman, J.P., Ross, E.A., Cooper, H.S., Meropol, N.J., Freedman, G., Pinover, W.H., LeVoyer, T.E., Sasson, A.R., Eisenberg, B.L. Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas. J. Gastrointest. Surg. 5:121-130, 2001.

Rothenberg, M.L., Meropol, N.J., Poplin, E.A., Van Cutsem, E., Wadler, S. Mortality associated with irinotecan + bolus 5-fluorouracil/leucovorin: summary findings of an independent panel. J. Clin. Oncol. 19(18):3801-3807, 2001.

Sasson, A.R., Hoffman, J.P., Ross, E., Meropol, N.J., Szarka, C.E., Freedman, G., Pinover, W., Pingpank, J.F., Eisenberg, B.L. Trimodality therapy for advanced gallbladder cancer. Am. Surg. 67:277-284, 2001.

Sweed, M.R., Meropol, N.J. Assessment, diagnosis, and staging. In Contemporary issues in colorectal cancer: a nursing perspective, edited by D.T. Berg. Jones and Bartlett Publishers, Sudbury, Massachusetts, pp. 65-79, 2001.

Szarka, C.E., Yao, K-S., Pfeiffer, G.R., Balshem, A.M., Litwin, S., Frucht, H., Goosenberg, E.B., Engstrom, P.F., Clapper, M.L., O'Dwyer, P.J. Chronic dosing of oltipraz in people at increased risk for colorectal cancer. Cancer Detect. Prev. 25: 352-361, 2001.

von Mehren, M., Arlen, P., Gulley, J., Rogatko, A., Cooper, H.S., Meropol, N.J., Alpaugh, R.K., Davey, M., McLaughlin, S., Beard, M.T., Tsang, K.Y., Schlom, J., Weiner, L.M. The influence of GM-CSF and prior chemotherapy on the immunologic response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin. Cancer Res. 7:1181-1191, 2001.

Weinberg, D.S., Heyt, G., Cavanagh, M., Pitchon, D., McGlynn, K.A., London, W.T. A case-control study of CCK and gastrin levels in pancreatic adenocarcinoma. Cancer Epidemiol. Biomark. Prev. 10:721-722, 2001.

Clapper ML, Chang W-C, Meropol, NJ. Chemoprevention of Colorectal Cancer. Curr Opinion Oncol 13: 307-313, 2001.

Sweed MR, Meropol NJ. Assessment, diagnosis, and staging. In: Contemporary issues in colorectal cancer: a nursing perspective. Berg DT, ed. Jones and Bartlett Publishers, Sudbury, Massachusetts, pp. 65-79, 2001.

Willett C, Ajani J, Kelsen D, Sigurdson E, Abrams R, Berkey B, Benetz M, Crane C, Gaspar L, Goodyear MD, Gunderson L, Haddock M, Hoffmann J, Janjan N, John M, Kachnic L, Krieg R, Landry J, Meropol N, Minsky B, Mitchell E, Mohiuddin M, Moulder J, Myerson R, Noyes D, Pajak TF, Raben D, Regine W, Rich T, Robertson JM, Russell A, Skibber J, Kim P; Radiation Therapy Oncology Group. Radiation Therapy Oncology Group. Research Plan 2002-2006. Gastrointestinal Cancer Committee. Int J Radiat Oncol Biol Phys 51:19-27, 2001.

Medical Oncology

Director, Gastrointestinal Cancer Program;
Director, Gastrointestinal Tumor Risk Assessment Program

Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111-2497

To make an appointment, call:
215-728-2570.

For general information, call:
1-888-FOX CHASE.
An oncology certified nurse will assist you.

Back to Dr. Meropol's Directory Page